Corporate News

Abivax SA (ABVX.PA) advanced modestly, closing up 1.32 % during a 24‑hour period that ended at 18:32 Central Europe on Thursday, 22 October 2026. The share price settled near EUR 81.7 on the principal exchanges, with a current market capitalization of approximately EUR 7.3 billion. Over the past 24 hours, roughly EUR 9.4 million of shares were traded, a figure that reflects a healthy, though not extraordinary, liquidity level. The company’s outstanding shares total 86.9 million, and its 200‑day simple moving average sits at EUR 99.83. The 52‑week high—EUR 139—was reached on 3 July 2026, while the 52‑week low—EUR 60.45—occurred on 3 March 2026.

Recent Analyst Coverage

Abivax has attracted renewed attention from several equity research houses. On Tuesday, Guggenheim reaffirmed a “buy” recommendation for the company, citing a notable upside potential in its valuation outlook. The rating was echoed by BTIG, Barclays, HC Wainwright, and Citizens Jmp, all of whom highlighted an encouraging price‑target trajectory. In contrast, Weiss Ratings issued a “sell (d‑)” note, reflecting a more cautious stance. The consensus market view places the stock as a moderate buy, and institutional investors and hedge funds have been active, with several entities increasing their holdings during the first half of the year.

The company’s pipeline continues to develop its lead oral therapeutic, obefazimod, aimed at chronic inflammatory and immune‑mediated diseases. In addition, Abivax is advancing several vaccine candidates for infectious diseases—including a Phase II candidate for HIV/AIDS (ABX 464), a therapeutic vaccine for chronic hepatitis B (ABX 203), and an immune‑enhancer (ABX 196). The firm’s broader portfolio includes candidates for typhoid, meningitis, leptospirosis, dengue, Ebola, and chikungunya, many of which are still in pre‑clinical stages.

In the same 24‑hour window, other French equities moved in a range of directions:

  • Gaztransport & Technigé (GTT.PA) – up 1.59 %, trading at EUR 198.5. Market cap: EUR 7.6 billion; P/E: 17.1.
  • Scor (SCR.PA) – up 0.36 %, trading at EUR 33.5. Market cap: EUR 6 billion; P/E: 7.44.
  • Compagnie du Cambodge (CBDG.PA) – down 1.58 %, trading at EUR 93.5. Market cap: EUR 5.7 billion; P/E: 223.26.
  • Sodexo (SW.PA) – down 0.87 %, trading at EUR 56.4. Market cap: EUR 8.3 billion; P/E: 19.13.
  • Spie (SPIE.PA) – up 1.53 %, trading at EUR 40.56. Market cap: EUR 7 billion; P/E: 23.23.

Bureau Veritas reported a robust third‑quarter performance, with revenue rising year‑on‑year and organic growth improving sequentially. The company’s LEAP 28 strategy has reshaped its portfolio into four product‑line‑centric divisions—Building & Infrastructure, Tests & Services, Industrial & Commodities, and Business Assurance—driving growth across the board. Positive contributions from recent bolt‑on acquisitions and a favorable currency environment supported the upward trend. The group maintains a solid balance sheet, having issued an A3 bond and continued its share‑buyback programme. Management reaffirmed its 2026 outlook, citing moderate to high single‑digit organic revenue growth and improving operating margins, while outlining plans to accelerate mergers and acquisitions and to expand AI‑related services as part of its long‑term growth strategy.

Spie also experienced gains, trading up 1.53 % to EUR 40.56. The company’s market cap stands at EUR 7 billion, with a P/E ratio of 23.23.

Atos Group reported that its third‑quarter 2026 performance continued its recovery trend. Organic revenue declined modestly compared with the previous year, but sequential improvement was evident, driven primarily by gains in the UK & Ireland, International Markets, and France. Operating cash generation reached a positive level for the first time since the Genesis transformation began, and liquidity strengthened to roughly €966 million. The company highlighted progress on its cost‑reduction programme, noting that savings targets were met ahead of schedule. Commercial activity reflected typical summer seasonality, with order entry rising and the book‑to‑bill ratio falling slightly. The group reaffirmed its 2026 targets of a modest revenue decline and a margin near seven percent, while signalling a focus on sustainable growth and further efficiency gains in the coming years.

Company Background

Abivax SA is a biotechnology company headquartered in Paris, France, that specializes in developing, marketing, and commercializing anti‑viral therapies and therapeutic vaccines for the treatment of infectious diseases in Asia and Latin America. The company’s flagship assets include:

  • ABX 464 – Phase II clinical trial for sustained viral remission or functional cure in HIV/AIDS patients.
  • ABX 203 – Therapeutic vaccine candidate in Phase IIb/III trials for chronic hepatitis B.
  • ABX 196 – Art immune enhancer candidate that completed Phase I trials for iNKT cells.

Additional vaccine programmes cover typhoid, meningitis B and C, and leptospirosis. The company’s pre‑clinical pipeline features ABX 220 for dengue fever, ABX 544 (a polyclonal antibody candidate for Ebola), and ABX 311 for chikungunya. Abivax has established license agreements with the French National Centre for Scientific Research, the University of Montpellier 2, and the Curie Institute, and maintains a partnership with the Cuban Centro de Ingeniería Genética y de Biotecnología. Founded in 2013, Abivax trades on NYSE Euronext Paris and maintains its official website at www.abivax.com .